 |
|
|
 |
Tau Joins APP in the Ironworks
3 February 2012. Could the answer to tau’s involvement in so many neurodegenerative conditions lie in its failure to perform a newly discovered role: promoting iron export?...
|
| |
|
Mice Tell Tale of Tau Transmission, Alzheimer’s Progression
3 February 2012. A study reported in the February 1 PLoS One offers an explanation for how tau pathology progresses in Alzheimer’s disease...
|
| |
|
Intracellular Aβ Causes Neurodegeneration in Mice
2 February 2012. A study injects new data into an ongoing debate about the role of intraneuronal Aβ...
|
| |
|
Would Congress Please SPRINT Toward Cures?
2 February 2012. At a press conference held today in Washington, D.C., congressional leaders introduced "The Spending Reductions Through Innovations in Therapies (SPRINT) Agenda Act of 2012”...
|
| |
GO TO ALL RESEARCH NEWS  |
|
|
 |
|
|
In the spotlight
|
 |
Ruckus Over Amyloid Imaging Agents
|
 |
|
|
|
|
Radiotracers binding fibrillar Aβ deposits allow researchers to
visualize one of the two hallmark pathologies of AD in the brains of living people. As the first of several such tracers seeks FDA approval for broader use beyond research studies, seven scientists from the fields of radiology and nuclear medicine have challenged the reliability of the technology, claiming the labeling is not specific for Aβ. Twenty-four leaders in AD research disputed the validity of the challenge, citing neuropathology evidence that shows the PET compounds accurately reflect Aβ deposits in the brain. The two sides published warring editorials in a nuclear medicine journal, which together have become the most downloaded articles in the journal’s recent history. Who’s right? Get a point-by-point rundown of the science and make up your own mind.
|
|
Image caption: Amyloid imaging of brain with Alzheimer's disease. (View larger image.) Image credit: W. Klunk, C. Mathis, University of Pittsburgh
|
|
|
|
Induced Human Neurons Yield Clues to AD
|
|
|
|
|
|
The ability to generate neurons from AD patients is opening doors to research. In the January 25 Nature, scientists describe the first neurons made from people with APP duplications and from people with sporadic AD. The findings follow last year’s report of induced neurons derived from people with presenilin gene mutations. |
|
The new neurons, which were made from induced pluripotent stem cells (iPSCs), appear to model several facets of AD pathology, including elevated production of Aβ, phosphorylated tau, and large endosomes. Intriguingly, the cells also suggest that tau pathology lies downstream of APP, but is not necessarily related to Aβ. Though the results come from only a handful of patients and need to be repeated, the data underscore the promise of iPSC technology. Read the full story.
|
|
|
|
Alzheimer's Challenge 2012: Win the Prize
|
|
|
|
|
|
Do you have a great idea for how to diagnose and track early Alzheimer's disease? The Alzheimer's Challenge 2012 presents an opportunity to turn your idea into cash. |
|
Co-sponsored by the Geoffrey Beene Gives Back® Alzheimer’s Initiative, the Alzheimer’s Immunotherapy Program of Janssen Alzheimer Immunotherapy, and Pfizer Inc., the prize seeks a simple, reliable, minimally invasive means to catch the earliest signs of Alzheimer's and follow them over time. Judges will award $300,000 in the first of a series of challenges aimed at jumpstarting research in the field of Alzheimer's disease. For more information, see news brief.
|
|
|
|
Register Online for Drug Discovery Conference and Save
|
|
|
|
|
|
Interested in turning your latest discovery into a life-saving drug? There’s still time to register for the 6th Drug Discovery for Neurodegeneration Conference, which takes place 12-14 February 2012, in New York City. |
|
Presented by the Alzheimer’s Drug Discovery Foundation, the conference will address the myriad steps, from high-throughput screening to investigational new drug applications, that must be taken to advance potential therapies into the clinic. The program will center around Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Registration will be available at the door, but sign up online to avoid the last minute rush and save yourself some money.
|
|
|
|
| |
|
| |
What's New
|
|
Comments - Posted 3 February 2012
Read remarks by Karl Herholz about
Moghbel MC et al.
NEWS: Love a Good Fight? Check Out Brouhaha Over Amyloid Imaging |
| |
|
Conferences - Posted 2 February 2012
8th World Stroke Congress: 10-13 October 2012, Brasilia, Brazil. |
| |
|
Comments - Posted 1 February 2012
Read remarks by Shaohua Xu
LIVE DISCUSSION: Clearing the Fog Around Aβ Oligomers |
| |
|
Comments - Posted 1 February 2012
Read remarks by Gunnar K. Gouras about
Israel MA et al.
NEWS: Induced Neurons From AD Patients Hint at Disease Mechanisms |
| |
|
Comments - Posted 1 February 2012
Read remarks by Hugo Geerts
NEWS: CONCERT Trial of Dimebon Falls Flat |
| |
|
Comments - Posted 1 February 2012
Read remarks by Patricia Zglinski about Merrilees J et al.
PAPER: Characterization of Apathy in Persons Wth Frontotemporal Dementia and the Impact on Family Caregivers. |
| |
|
Comments - Posted 1 February 2012
Read remarks by Cathy Roe about Landau SM et al.
PAPER: Association of Lifetime Cognitive Engagement and Low β-Amyloid Deposition. |
| |
|
Jobs - Posted 30 January 2012
Alzheimer's Disease Translational Research Fellowship: Boston University, Boston, Massachusetts. |
SEE MORE |
|
|
|
|
Home
Check out our ongoing Forum Webinar: 
